135 related articles for article (PubMed ID: 33799060)
1. Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.
Schasfoort RBM; van Weperen J; van Amsterdam M; Parisot J; Hendriks J; Koerselman M; Karperien M; Mentink A; Bennink M; Krabbe H; Terstappen LW; Mulder AHL
Biosens Bioelectron; 2021 Jul; 183():113165. PubMed ID: 33799060
[TBL] [Abstract][Full Text] [Related]
2. High throughput surface plasmon resonance imaging method for clinical detection of presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.
Schasfoort RBM; van Weperen J; van Amsterdam M; Parisot J; Hendriks J; Koerselman M; Karperien M; Mentink A; Bennink M; Krabbe H; Terstappen LW; Mulder AHL
MethodsX; 2021; 8():101432. PubMed ID: 34221910
[TBL] [Abstract][Full Text] [Related]
3. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
4. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
[TBL] [Abstract][Full Text] [Related]
5. Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.
Servian CDP; Spadafora-Ferreira M; Dos Anjos DCC; Guilarde AO; Gomes-Junior AR; Borges MASB; Masson LC; Silva JMM; de Lima MHA; Moraes BGN; Souza SM; Xavier LE; de Oliveira DCA; Batalha-Carvalho JV; Moro AM; Bocca AL; Pfrimer IAH; Costa NL; Feres VCR; Fiaccadori FS; Souza M; Gardinassi LG; Durigon EL; Romão PRT; Jorge SAC; Coelho V; Botosso VF; Fonseca SG
Front Immunol; 2023; 14():1206979. PubMed ID: 37876932
[TBL] [Abstract][Full Text] [Related]
6. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study.
Amellal H; Assaid N; Charoute H; Akarid K; Maaroufi A; Ezzikouri S; Sarih M
PLoS One; 2023; 18(7):e0288557. PubMed ID: 37437051
[TBL] [Abstract][Full Text] [Related]
8. High Titers of Low Affinity Antibodies in COVID-19 Patients Are Associated With Disease Severity.
Hendriks J; Schasfoort R; Koerselman M; Dannenberg M; Cornet AD; Beishuizen A; van der Palen J; Krabbe J; Mulder AHL; Karperien M
Front Immunol; 2022; 13():867716. PubMed ID: 35493512
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.
Demers-Mathieu V; DaPra C; Medo E
Breastfeed Med; 2021 May; 16(5):393-401. PubMed ID: 33835835
[No Abstract] [Full Text] [Related]
10. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
[TBL] [Abstract][Full Text] [Related]
11. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients.
Liao B; Chen Z; Zheng P; Li L; Zhuo J; Li F; Li S; Chen D; Wen C; Cai W; Wu S; Tang Y; Duan L; Wei P; Chen F; Yuan J; Yang J; Feng J; Zhao J; Zhao J; Sun B; Zhu A; Li Y; Tang X
Front Immunol; 2021; 12():724763. PubMed ID: 34489978
[TBL] [Abstract][Full Text] [Related]
12. Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease.
Brynjolfsson SF; Sigurgrimsdottir H; Einarsdottir ED; Bjornsdottir GA; Armannsdottir B; Baldvinsdottir GE; Bjarnason A; Gudlaugsson O; Gudmundsson S; Sigurdardottir ST; Love A; Kristinsson KG; Ludviksson BR
Front Immunol; 2021; 12():695230. PubMed ID: 34177962
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
[TBL] [Abstract][Full Text] [Related]
14. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design.
Scheiblauer H; Nübling CM; Wolf T; Khodamoradi Y; Bellinghausen C; Sonntagbauer M; Esser-Nobis K; Filomena A; Mahler V; Maier TJ; Stephan C
J Clin Virol; 2022 Jan; 146():105052. PubMed ID: 34920374
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
[TBL] [Abstract][Full Text] [Related]
16. Detection of IgM, IgG, IgA and neutralizing antibody responses to SARS-CoV-2 infection and mRNA vaccination.
Fleischmann CJ; Bulman CA; Yun C; Lynch KL; Wu AHB; Whitman JD
J Med Microbiol; 2023 Jan; 72(1):. PubMed ID: 36748419
[No Abstract] [Full Text] [Related]
17. Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection.
Abou-Saleh H; Abo-Halawa BY; Younes S; Younes N; Al-Sadeq DW; Shurrab FM; Liu N; Qotba H; Al-Dewik N; Ismail A; Yassine HM; Abu-Raddad LJ; Nasrallah GK
J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36342115
[TBL] [Abstract][Full Text] [Related]
18. Characterization of SARS-CoV-2 humoral immune response in a subject with unique sampling: A case report.
Walker MR; Idorn M; Bennett A; Søgaard M; Salanti A; Ditlev SB; Barfod L
Immun Inflamm Dis; 2023 Jun; 11(6):e910. PubMed ID: 37382252
[TBL] [Abstract][Full Text] [Related]
19. Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies.
Infantino M; Manfredi M; Grossi V; Lari B; Fabbri S; Benucci M; Fortini A; Damiani A; Mobilia EM; Panciroli M; Pancani S; Pesce G
J Med Virol; 2021 Mar; 93(3):1436-1442. PubMed ID: 32790181
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Cross-sectional and Longitudinal HLA and Anti-viral Responses After COVID Infection in Renal Allograft Recipients: Differences and Correlates.
Girnita AL; Wang L; Colovai AI; Ahearn P; Azzi Y; Menon MC; Fernandez-Vina M; Gebel HM; Steve Woodle E; Cravedi P; Maltzman JS; Akalin E
Transplantation; 2022 Oct; 106(10):2085-2091. PubMed ID: 36070571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
